Literature DB >> 6503634

Determinants for hepatitis B e antigen clearance in chronic type B hepatitis.

Y F Liaw, C M Chu, M J Huang, I S Sheen, C Y Yang, D Y Lin.   

Abstract

A 6-year (mean 24.5 months) longitudinal study has been undertaken in 237 HBeAg-positive patients with clinicopathologically verified chronic hepatitis. HBeAg clearance occurred in 74 patients at a rate of 16% per year, and a cumulative probability of 67% at the end of a 5-year follow-up. HBeAg clearance was preceded by a temporary "exacerbation" with SGPT greater than 300 IU/L in 62% of the patients. On the other hand, irrespective of the level of SGPT elevation, only 23% of such exacerbations were followed by HBeAg clearance. Further analysis indicates that alphafetoprotein greater than 100 ng/ml, frequently associated with bridging hepatic necrosis, during "exacerbation" predicts HBeAg clearance. In addition, patients with chronic lobular hepatitis and chronic active hepatitis have a higher annual HBeAg clearance rate than patients with chronic persistent hepatitis and nonspecific histologic changes (greater than 15% vs less than 8%, P less than 0.03). Short-term immunosuppressive treatment did not delay HBeAg seroconversion. Male patients had a higher annual HBeAg clearance rate than female patients (18.2% vs 8.7%, P less than 0.05). It was concluded that, in addition to the time factor, the nature of chronic hepatitis, the extent of hepatic damage during "exacerbation", and the sex of the patients are important determinants for HBeAg clearance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6503634     DOI: 10.1111/j.1600-0676.1984.tb00942.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  9 in total

1.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

Review 2.  Natural history of chronic hepatitis B: phases in a complex relationship.

Authors:  Catherine M N Croagh; John S Lubel
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

3.  Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation.

Authors:  Cheng-Yuan Peng; Chih-Bin Chen; Hsueh-Chou Lai; Wen-Pang Su; Po-Heng Chuang; Hong-Dar Isaac Wu; Long-Bin Jeng
Journal:  Hepatol Int       Date:  2010-12-16       Impact factor: 6.047

4.  Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response.

Authors:  M G Brook; J A McDonald; P Karayiannis; L Caruso; G Forster; J R Harris; H C Thomas
Journal:  Gut       Date:  1989-08       Impact factor: 23.059

5.  Analysis of intrahepatic HBVDNA in serologic HBV markers-negative or HBsAg-negative patients with chronic hepatitis.

Authors:  Y Y Zhang; Z Q Yu; L J Hao
Journal:  J Tongji Med Univ       Date:  1992

6.  Management of chronic hepatitis B: consensus guidelines.

Authors:  Morris Sherman; Stephen Shafran; Kelly Burak; Karen Doucette; Winnie Wong; Nigel Girgrah; Eric Yoshida; Eberhard Renner; Philip Wong; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2007-06       Impact factor: 3.522

7.  On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study.

Authors:  Yi-Cheng Chen; Chao-Wei Hsu; Ming-Yang Chang; Chau-Ting Yeh
Journal:  BMC Res Notes       Date:  2013-09-02

8.  Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver.

Authors:  Sung Kwan Bae; Hiroshi Yatsuhashi; Satoru Hashimoto; Yasuhide Motoyoshi; Eisuke Ozawa; Shinya Nagaoka; Seigo Abiru; Atsumasa Komori; Kiyoshi Migita; Minoru Nakamura; Masahiro Ito; Yuzo Miyakawa; Hiromi Ishibashi
Journal:  Med Sci Monit       Date:  2012-12

Review 9.  Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma.

Authors:  Hira Hanif; Mukarram Jamat Ali; Ammu T Susheela; Iman Waheed Khan; Maria Alejandra Luna-Cuadros; Muzammil Muhammad Khan; Daryl Tan-Yeung Lau
Journal:  World J Gastroenterol       Date:  2022-01-14       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.